83 results
DEFM14A
ORTX
Orchard Therapeutics plc
16 Nov 23
Proxy related to merger
4:45pm
and Cosmetic Act of 1938, as amended, other U.S. and foreign healthcare laws applicable to Orchard and its subsidiaries and the Controlled Substances Act … Capital”), by RA Capital Healthcare Fund, L.P. (the “Fund”), Peter Kolchinsky and Rajeev Shah on March 20, 2023, consists of (i) 16,720,000 ordinary shares
8-K
EX-99.1
ORTX
Orchard Therapeutics plc
13 Nov 23
Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Accomplishments
7:05am
and Healthcare products Regulatory Agency (MHRA).
Commercial Updates and Newborn Screening Progress
In October, the Institute for Clinical and Economic Review
PREM14A
ORTX
Orchard Therapeutics plc
3 Nov 23
Preliminary proxy related to merger
5:11pm
with the U.S. Food, Drug and Cosmetic Act of 1938, as amended, other U.S. and foreign healthcare laws applicable to Orchard and its subsidiaries … on a Schedule 13G filed with the SEC by RA Capital Management L.P. (“RA Capital”), by RA Capital Healthcare Fund, L.P. (the “Fund”), Peter Kolchinsky
DEFA14A
ORTX
Orchard Therapeutics plc
17 Oct 23
Additional proxy soliciting materials
4:32pm
, talk and interact with the world around them. Libmeldy is approved by the European Commission (EC) and UK Medicines and Healthcare products … Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of “late infantile” and “early juvenile” MLD patients. It is currently
DEFA14C
mw69a 0nywcef6s1a
5 Oct 23
Additional information
4:48pm
DEFA14C
j4w9ui6
5 Oct 23
Additional information
4:45pm
DEFA14C
ptfe 17ps
5 Oct 23
Additional information
4:40pm
DEFA14A
aqq3a5jg1swkq
5 Oct 23
Additional proxy soliciting materials
9:07am
8-K
EX-99.1
9ff 371gtz
5 Oct 23
Kyowa Kirin to Acquire Orchard Therapeutics
9:05am
8-K
EX-2.1
rj3e6y8mhzij 7xo4v
5 Oct 23
Kyowa Kirin to Acquire Orchard Therapeutics
9:05am
8-K
EX-99.1
1ua6ct
18 Sep 23
Orchard Therapeutics Announces Acceptance of Biologics License Application for OTL-200 in MLD and Receives Priority Review
7:07am
424B3
re2nkm
21 Aug 23
Prospectus supplement
4:32pm
8-K
EX-99.1
0iq8y6ea
3 Aug 23
Orchard Therapeutics Completes Submission of Biologics License Application for OTL-200 in MLD to U.S. FDA
7:05am
8-K
EX-99.1
jpuyx
26 Jun 23
Resulting in $34 Million of Additional Capital
7:06am
8-K
EX-99.1
h0h8fu8z9q
15 May 23
OTL-200 Biologics License Application (BLA) submission completion anticipated in mid-2023
7:05am